Frusciante L, Geminiani M, Shabab B, Olmastroni T, Roncucci N, Mastroeni P
Int J Mol Sci. 2025; 26(2).
PMID: 39859264
PMC: 11765263.
DOI: 10.3390/ijms26020548.
Zhong B, Zhang Y, Zheng H, Chen Q, Lu H, Chen X
Acta Pharmacol Sin. 2024; .
PMID: 39587283
DOI: 10.1038/s41401-024-01418-1.
Hayakawa D, Watanabe Y, Gouda H
J Chem Inf Model. 2024; 64(15):6003-6013.
PMID: 39012240
PMC: 11323840.
DOI: 10.1021/acs.jcim.4c00896.
Crocetti L, Khlebnikov A, Guerrini G, Schepetkin I, Melani F, Giovannoni M
Molecules. 2024; 29(11).
PMID: 38893295
PMC: 11173647.
DOI: 10.3390/molecules29112421.
Yoon H, Park G, Balupuri A, Kang N
Comput Struct Biotechnol J. 2023; 21:4683-4696.
PMID: 37841326
PMC: 10568351.
DOI: 10.1016/j.csbj.2023.09.037.
How many kinases are druggable? A review of our current understanding.
Anderson B, Rosston P, Ong H, Hossain M, Davis-Gilbert Z, Drewry D
Biochem J. 2023; 480(16):1331-1363.
PMID: 37642371
PMC: 10586788.
DOI: 10.1042/BCJ20220217.
Novel Tryptanthrin Derivatives with Selectivity as -Jun N-Terminal Kinase (JNK) 3 Inhibitors.
Schepetkin I, Karpenko O, Kovrizhina A, Kirpotina L, Khlebnikov A, Chekal S
Molecules. 2023; 28(12).
PMID: 37375361
PMC: 10304880.
DOI: 10.3390/molecules28124806.
Fragment-Based and Structural Investigation for Discovery of JNK3 Inhibitors.
Duong M, Ahn H
Pharmaceutics. 2022; 14(9).
PMID: 36145648
PMC: 9501523.
DOI: 10.3390/pharmaceutics14091900.
Identifying New Ligands for JNK3 by Fluorescence Thermal Shift Assays and Native Mass Spectrometry.
Cheng C, Liu M, Gao X, Wu D, Pu M, Ma J
ACS Omega. 2022; 7(16):13925-13931.
PMID: 35559183
PMC: 9088906.
DOI: 10.1021/acsomega.2c00340.
JNK Mediates Differentiation, Cell Polarity and Apoptosis During Amphioxus Development by Regulating Actin Cytoskeleton Dynamics and ERK Signalling.
Somorjai I, Ehebauer M, Escriva H, Garcia-Fernandez J
Front Cell Dev Biol. 2021; 9:749806.
PMID: 34778260
PMC: 8586503.
DOI: 10.3389/fcell.2021.749806.
Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats.
Zulfiqar Z, Shah F, Shafique S, Alattar A, Ali T, Alvi A
J Inflamm Res. 2021; 13:1185-1205.
PMID: 33384558
PMC: 7770337.
DOI: 10.2147/JIR.S284471.
c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases.
Rehfeldt S, Majolo F, Goettert M, Laufer S
Int J Mol Sci. 2020; 21(24).
PMID: 33352989
PMC: 7765872.
DOI: 10.3390/ijms21249677.
Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3.
Ansideri F, Macedo J, Eitel M, El-Gokha A, Zinad D, Scarpellini C
ACS Omega. 2018; 3(7):7809-7831.
PMID: 30087925
PMC: 6072243.
DOI: 10.1021/acsomega.8b00668.
New insights into the structural dynamics of the kinase JNK3.
Mishra P, Gunther S
Sci Rep. 2018; 8(1):9435.
PMID: 29930333
PMC: 6013471.
DOI: 10.1038/s41598-018-27867-3.
Parametrization of halogen bonds in the CHARMM general force field: Improved treatment of ligand-protein interactions.
Soteras Gutierrez I, Lin F, Vanommeslaeghe K, Lemkul J, Armacost K, Brooks 3rd C
Bioorg Med Chem. 2016; 24(20):4812-4825.
PMID: 27353885
PMC: 5053860.
DOI: 10.1016/j.bmc.2016.06.034.
Considerations of Protein Subpockets in Fragment-Based Drug Design.
Bartolowits M, Davisson V
Chem Biol Drug Des. 2015; 87(1):5-20.
PMID: 26307335
PMC: 5464946.
DOI: 10.1111/cbdd.12631.
Anthrapyrazolone analogues intercept inflammatory JNK signals to moderate endotoxin induced septic shock.
Prasad K, Trinath J, Biswas A, Sekar K, Balaji K, Guru Row T
Sci Rep. 2014; 4:7214.
PMID: 25428720
PMC: 4245532.
DOI: 10.1038/srep07214.
Automating crystallographic structure solution and refinement of protein-ligand complexes.
Echols N, Moriarty N, Klei H, Afonine P, Bunkoczi G, Headd J
Acta Crystallogr D Biol Crystallogr. 2014; 70(Pt 1):144-54.
PMID: 24419387
PMC: 3919266.
DOI: 10.1107/S139900471302748X.
Arrestin-dependent activation of JNK family kinases.
Zhan X, Kook S, Gurevich E, Gurevich V
Handb Exp Pharmacol. 2013; 219:259-80.
PMID: 24292834
PMC: 4514028.
DOI: 10.1007/978-3-642-41199-1_13.
Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance.
Stogios P, Spanogiannopoulos P, Evdokimova E, Egorova O, Shakya T, Todorovic N
Biochem J. 2013; 454(2):191-200.
PMID: 23758273
PMC: 3743924.
DOI: 10.1042/BJ20130317.